DOP20070101A - Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida. - Google Patents

Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.

Info

Publication number
DOP20070101A
DOP20070101A DO2007P000101A DOP20070101A DOP20070101A DO P20070101 A DOP20070101 A DO P20070101A DO 2007P000101 A DO2007P000101 A DO 2007P000101A DO P20070101 A DOP20070101 A DO P20070101A DO P20070101 A DOP20070101 A DO P20070101A
Authority
DO
Dominican Republic
Prior art keywords
humanized
human
function
integrin
reduced immunogenicity
Prior art date
Application number
DO2007P000101A
Other languages
English (en)
Inventor
Andreas Menrad
Joerg Willuda
Klaus Bosslet
Dieter Zopf
Heike Petrul
Stefan Steidl
Josef Prassler
Corinne Petit-Frere
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of DOP20070101A publication Critical patent/DOP20070101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

POLIPEPTIDOS RECOMBINANTES HUMANOS O HUMANIZADOS QUE SE UNEN A LA INTEGRINA ?5?1 CON GRAN AFINIDAD Y BLOQUEAN SU FUNCION. ADEMAS, SE DESCRIBEN APLICACIONES DE DIAGNOSTICO Y FARMACEUTICO DE LOS POLIPEPTIDOS.
DO2007P000101A 2006-05-24 2007-05-22 Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida. DOP20070101A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
DOP20070101A true DOP20070101A (es) 2007-12-30

Family

ID=38659612

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2007000101A DOP2007000101A (es) 2006-05-24 2007-05-22 Anticuerpos bloqueantes de la función de la integrina a5b1 humanos y humanizados de gran afinidad con inmunogenicidad reducida
DO2007P000101A DOP20070101A (es) 2006-05-24 2007-05-22 Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2007000101A DOP2007000101A (es) 2006-05-24 2007-05-22 Anticuerpos bloqueantes de la función de la integrina a5b1 humanos y humanizados de gran afinidad con inmunogenicidad reducida

Country Status (23)

Country Link
US (1) US20090081207A1 (es)
EP (1) EP2032605A2 (es)
JP (1) JP2009537158A (es)
KR (1) KR20090027218A (es)
CN (1) CN101495515A (es)
AR (1) AR061107A1 (es)
AU (1) AU2007253586A1 (es)
BR (1) BRPI0711796A2 (es)
CA (1) CA2652886A1 (es)
CL (1) CL2007001488A1 (es)
CR (1) CR10456A (es)
DO (2) DOP2007000101A (es)
EA (1) EA200802348A1 (es)
EC (1) ECSP088909A (es)
MA (1) MA30425B1 (es)
MX (1) MX2008014910A (es)
NO (1) NO20085362L (es)
PE (1) PE20080100A1 (es)
TN (1) TNSN08469A1 (es)
TW (1) TW200817433A (es)
UY (1) UY30362A1 (es)
WO (1) WO2007134876A2 (es)
ZA (1) ZA200810850B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
NZ615012A (en) 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
MY151191A (en) 2007-09-26 2014-04-30 Genentech Inc Novel antibodies
EP2650017A3 (en) * 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
EP2356154A4 (en) * 2008-11-06 2012-12-19 Alexion Pharma Inc DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
CA2748158A1 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
NZ594343A (en) * 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
UA115544C2 (uk) 2012-03-13 2017-11-27 Респіверт Лімітед Спосіб підвищення стабільності до хімічного розкладання фармацевтичної композиції та застосування стабілізуючого агента у фармацевтичній коипозиції
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
WO2014105910A1 (en) * 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2017001990A1 (en) * 2015-06-28 2017-01-05 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
CN113557246B (zh) * 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
DK1755659T3 (da) * 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
NZ615012A (en) * 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists

Also Published As

Publication number Publication date
EP2032605A2 (en) 2009-03-11
NO20085362L (no) 2009-02-23
PE20080100A1 (es) 2008-04-18
JP2009537158A (ja) 2009-10-29
UY30362A1 (es) 2008-01-02
CL2007001488A1 (es) 2008-01-04
BRPI0711796A2 (pt) 2011-12-06
AU2007253586A1 (en) 2007-11-29
WO2007134876A8 (en) 2009-07-02
TW200817433A (en) 2008-04-16
ECSP088909A (es) 2008-12-30
MA30425B1 (fr) 2009-05-04
ZA200810850B (en) 2010-05-26
TNSN08469A1 (en) 2010-04-14
CR10456A (es) 2009-02-26
CN101495515A (zh) 2009-07-29
CA2652886A1 (en) 2007-11-29
AR061107A1 (es) 2008-08-06
MX2008014910A (es) 2009-01-23
WO2007134876A2 (en) 2007-11-29
WO2007134876A3 (en) 2008-03-27
US20090081207A1 (en) 2009-03-26
DOP2007000101A (es) 2007-12-31
EA200802348A1 (ru) 2009-08-28
KR20090027218A (ko) 2009-03-16

Similar Documents

Publication Publication Date Title
DOP20070101A (es) Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
EP4271413A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND ITS USES
CR20140398A (es) Anticuerpos e inmunoconjugados anti-cd22
IL164021A (en) Anti-alphavbeta6 antibodies and pharmaceutical compositions containing the same
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
HUE044756T2 (hu) HER-3 elleni antitestek és alkalmazásuk
DE60202841D1 (de) Anzeigegerät mit Drahtgitter-Strahlteiler und Kompensator
BRPI0717367A2 (pt) Di-hidropirazolonas substituídas e sua aplicação.
DK1904104T3 (da) SP35-antistoffer og anvendelser heraf
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
NL1026028A1 (nl) Cannabinoïdreceptorliganden en toepassingen daarvan.
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
HN2006015949A (es) Anticuerpos de p-caderina
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
ES2448492T8 (es) Procedimientos para la envoltura conjunta de bolsas con su contenido, y máquina de aplicación
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
EP4105237A4 (en) ANTI-CLDN18.2 ANTIBODIES AND ITS USE
EP4380631A4 (en) Cd3 targeting antibodies and uses thereof
EP4215547A4 (en) SINGLE-DOMAIN ANTIBODY TARGETING 4-1BB, ITS FUSION PROTEIN, PHARMACEUTICAL COMPOSITION AND USE THEREOF
BR0207616B1 (pt) material composto de policarbonato em camadas e seu uso.
DE602005006062D1 (de) Plättchenförmige Komposit-Partikeln und Kosmetika enthaltend die selben
EP4389771A4 (en) Fusion protein containing an anti-Tigit antibody and a TGF-beta receptor, and pharmaceutical composition and associated use